🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's series of deals with the US administration are "lacking a solid foundation." This comes after revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond broad headline terms contained within government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, hailed as a "significant" achievement, is still an "broad understanding" without detailed provisions. Observers point out that the press releases from the UK and US governments frame the deal in divergent terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has agreed to terms to raise drug prices in return for only a pledge from President Trump," said David Henig, a trade expert. "History shows he has a record of not keeping promises."

Broader Instability and a Paused Tech Deal

Concerns have been heightened by Washington's recent decision to pause the high-value digital accord, which was previously described as "a huge leap forward" in the bilateral relationship. The US claimed a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have still not been formally signed off by the US, despite a looming January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have admitted unease that the government's US-UK accords are flimsy and unreliable. One minister described the series of agreements as "built on sand," while another described the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Government figures have sought to reduce the chances of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that unpredictability is inherent in dealing with the Trump administration. However, they contend that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Yet, problems have emerged in enacting the May tariff agreement. Promised access for British beef have failed to be approved, and the commitment to "eliminate duties on UK metals" has is still pending, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.